0Studies tracked
0Claims cite
0Videos use
Average study score: 72/100
Bibliography
Studies by this author
1 study attributed to Wojciech Michalak on the platform. Click a card to read the full analysis.
Study
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)
First interim analysis of the SCORE study, a retrospective real-world cohort, aimed to assess the risk of major adverse cardiovascular events (MACE) among US adults with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg versus non-use.